133 related articles for article (PubMed ID: 24092808)
1. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
2. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
[TBL] [Abstract][Full Text] [Related]
3. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
4. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
[TBL] [Abstract][Full Text] [Related]
5. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
6. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
7. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):778-84. PubMed ID: 11473729
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Washiro M; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Sugimoto T; Seki N; Miyazaki M
J Cancer Res Clin Oncol; 2008 Jul; 134(7):793-801. PubMed ID: 18204862
[TBL] [Abstract][Full Text] [Related]
9. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
10. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Harris LN; Broadwater G; Abu-Khalaf M; Cowan D; Thor AD; Budman D; Cirrincione CT; Berry DA; Winer EP; Hudis CA; Hayes DF; Friedman P; Ellis M; Dressler L
J Clin Oncol; 2009 Jul; 27(21):3430-6. PubMed ID: 19470942
[TBL] [Abstract][Full Text] [Related]
12. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
13. Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.
Pett L; Kiakos K; Satam V; Patil P; Laughlin-Toth S; Gregory M; Bowerman M; Olson K; Savagian M; Lee M; Lee M; Wilson WD; Hochhauser D; Hartley JA
Biochim Biophys Acta Gene Regul Mech; 2017 May; 1860(5):617-629. PubMed ID: 27750031
[TBL] [Abstract][Full Text] [Related]
14. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
15. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
16. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
18. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
19. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T
Cancer Res; 2000 May; 60(9):2429-34. PubMed ID: 10811120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
